Mounjaro 15mg: reaching the highest dose and what to expect

What the decision to move to 15mg actually hinges on

Reaching 15mg is not a foregone conclusion. The licensed titration schedule for tirzepatide runs through six strengths (2.5mg, 5mg, 7.5mg, 10mg, 12.5mg and finally 15mg) with each step taken roughly every four weeks, subject to tolerance. The 2.5mg starting dose exists to let your body adjust to the medicine; therapeutic weight loss generally builds as the dose rises. By the time 15mg comes into view, you and your prescriber will have around five months of data: how much weight you have lost, how well you have tolerated each increase, and whether the higher dose is both safe and worthwhile for you.

The core question at this stage is clinical fit, not simply desire for the strongest option. Some people lose substantial weight at 10mg or 12.5mg and see diminishing returns from the final step; others plateau and genuinely benefit from moving up. If you are researching the full picture before starting, our overview of Mounjaro covers the treatment from the beginning, including how eligibility is assessed. The licensed eligibility criteria for Mounjaro as a weight-management medicine are a BMI of 30 or above, or 27 or above alongside at least one weight-related condition such as high blood pressure, type 2 diabetes or raised cholesterol. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance.

NICE's appraisal of tirzepatide (TA1026) sets out the recommended criteria for NHS access, but private prescribing follows the licensed criteria directly. Either way, it is a prescriber's clinical judgement (not a self-assessment) that authorises the step to the highest dose.

What the SURMOUNT-1 evidence says about 15mg results

The headline figures from SURMOUNT-1, published in the New England Journal of Medicine, are worth understanding precisely, because they are sometimes repeated without context. The trial randomised 2,539 adults with obesity (without type 2 diabetes) to tirzepatide or placebo over 72 weeks, alongside a reduced-calorie diet and activity programme. At the 15mg dose, participants saw an average body-weight reduction of around 20–21%; some analyses placed the figure slightly higher. That is a meaningful result, larger than any dose below it, and larger than semaglutide 2.4mg in the subsequent SURMOUNT-5 head-to-head trial.

Two caveats matter. First, these are averages across a trial population; individual outcomes vary with starting weight, adherence, diet and activity. Second, participants in SURMOUNT-1 followed structured lifestyle support throughout, the medicine worked alongside behavioural change, not instead of it. Reading more about tirzepatide 15mg and what the trial evidence means in practice can help set realistic expectations before a consultation.

For anyone comparing the 15mg results with lower doses, the Mounjaro 2.5mg starting dose offers useful context on where the titration journey begins and what those early weeks are designed to achieve. The 5mg data offer a useful reference point too: Mounjaro 5mg produced around 16% average weight loss in the same trial, illustrating how each step up contributes incrementally rather than dramatically. The gap between 12.5mg and 15mg is real but narrower than the earlier steps.

Side effects at the highest dose and how to manage the transition

Gastrointestinal effects are the most commonly reported side effects of tirzepatide at any dose, and they tend to be most noticeable in the first week or two after an increase. At 15mg that can mean nausea, loose stools, constipation, indigestion or a general sense of stomach unsettledness. For most people these settle as the body adjusts, though they do not disappear entirely for everyone.

A point our prescribers are asked about most weeks: should you stay longer at 12.5mg before stepping up if you are still experiencing side effects? That is precisely the kind of decision a prescriber makes with you rather than one you should navigate alone. Pushing through significant nausea without clinical guidance is not advisable. The guide to feeling faint on Mounjaro covers a related set of symptoms (dizziness and lightheadedness) that some people notice around dose changes.

Storage remains the same at every dose: keep the pen refrigerated between 2°C and 8°C, and check the Patient Information Leaflet for the exact window if the pen has been out of the fridge, a lot of people leave it in the fridge door next to everyday items, which works well as a reminder. If you have any questions about symptoms after an increase, the faqs page covers common concerns, and our support team is available seven days a week.

The NHS medicines page for tirzepatide on nhs.uk lists all recognised side effects and the signs that should prompt prompt medical attention: severe or persistent stomach pain that radiates to the back, signs of an allergic reaction, or symptoms of gallbladder problems. These are uncommon but worth knowing. Always report suspected side effects via the MHRA's Yellow Card scheme.

Cost and the route to 15mg through a private prescriber

Because the dose schedule takes several months, most people reach 15mg having already built a relationship with their prescribing service. The cost of each pen varies by dose; you can find the current context around Mounjaro pricing in the UK, including how private prices have shifted since Eli Lilly adjusted its UK list price from September 2025. It is worth knowing that the 15mg pen commands the highest price of the range, that is simply a function of the manufacturer's list price, not a service mark-up.

At nume, a prescriber personally reviews each dose increase rather than approving it automatically. That review covers your current weight evidence, how you have tolerated the previous dose, and whether 15mg is the appropriate next step. The free consultation is where that clinical relationship begins for new patients. If you are already on treatment elsewhere and considering a transfer, our about us page explains how evidence-checked transfers work and what to expect from our clinical team.

For a broader view of injectable and oral weight-loss options alongside tirzepatide, the weight-loss treatments overview sets out what is currently licensed in the UK and how the medicines compare. Mounjaro 15mg sits at the top of one of those pathways, not the starting point, but often a meaningful destination for people who respond well and tolerate the titration.